Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is ARA-290 | Erythropoietin-Derived Peptide for Tissue-Protective Receptor Research

Research Use Only Notice: This article discusses ARA-290 only as a laboratory research material. It is intended for trained researchers carrying out analytical tests, in-vitro experiments, or approved laboratory animal studies.

It is not intended for human or veterinary use. The laboratory calculations and handling information below must not be treated as administration or dosing instructions.

Related research products: ARA290 and ARA Water (PBS), the PBS reconstitution solvent for ARA-290. For laboratory research use only.

ARA-290, also called cibinetide or pHBSP, is a synthetic 11-amino-acid peptide. It was designed as a surface-mimetic peptide comprising eight residues from the aqueous face of erythropoietin (EPO) helix B (QEQLERAL) and three residues from the proximal BC loop (NSS).

What Is ARA-290

Its N-terminal glutamine is cyclized to pyroglutamate. The free peptide has a molecular formula of C51H84N16O21, an average molecular weight of 1,257.3 g/mol, a monoisotopic mass of 1,256.5997 Da, and CAS number 1208243-50-8.[1]

ARA-290 was designed from amino acids found on the water-facing surface of helix B in EPO. It is often described as an EPO-derived peptide, but it is not simply a continuous piece cut from the EPO protein.

Rather, amino acids that sit close together on the three-dimensional surface of helix B were selected, together with three residues from the adjacent BC loop region, to form a single linear peptide.[2]

Molecular Profile

Property Value
Primary name Cibinetide
Common research names ARA-290, ARA290, pHBSP, PHBSP
Sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
PubChem sequence field XEQLERALNSS; in this record the N-terminal modified residue is identified in the HELM notation as [Glp]
Length 11 amino-acid residues
Molecular formula C51H84N16O21
Average molecular weight 1,257.3 g/mol for the free peptide
Monoisotopic mass 1,256.5997 Da[1]
CAS number 1208243-50-8
N-terminus Pyroglutamate, also written pGlu, Pyr, or [Glp] in HELM notation
C-terminus Free carboxyl group
Disulfide bonds None expected because the sequence contains no cysteine
Purity Must be taken from the COA for the specific batch

The formula, average molecular weight, monoisotopic mass, and CAS number above describe the free peptide recorded in PubChem.[1] A supplied batch may also contain acetate, trifluoroacetate, water, or other non-peptide material.

For this reason, the vial weight may not equal the actual amount of peptide. Researchers should check the batch COA for peptide content, counterion content, and water content.

How ARA-290 Was Designed

The original 2008 study by Brines et al. tested short peptides based on the exposed surface of EPO helix B. The researchers selected eight amino acids from the aqueous face of helix B (QEQLERAL) and three residues from the adjacent BC loop (NSS), and formed a peptide with an N-terminal pyroglutamate residue from cyclization of the N-terminal glutamine.

They tested this peptide—termed pHBSP (pyroglutamate helix B surface peptide)—in cell experiments and laboratory animal models.[2]

In the tests reported in that study, the peptide produced several tissue-response signals without showing detectable red-blood-cell-forming activity in the assays used by the researchers.[2] This result applies only to the tested methods and conditions.

It should not be rewritten as a claim that ARA-290 has zero activity at every other receptor or under every possible condition.

What the Receptor Evidence Says

An early research model proposed that some EPO-related tissue signals involve both the EPO receptor (EPOR) and the beta-common receptor (CD131, also called βcR). Brines et al. (2004) reported that membrane proteins from rat brain, heart, liver, and kidney showed EPOR and βcR in a complex after EPO or carbamylated EPO (CEpo) affinity purification.

Anti-EPOR antibodies co-immunoprecipitated βcR from P19 mouse neuroblastoma cell membranes, and both receptor subunits co-localized in spinal cord neurons and cardiomyocytes by immunocytochemistry. Critically, neither EPO nor CEpo showed tissue-protective activity in cardiomyocyte or spinal cord injury models performed in βcR knockout mice, supporting a functional link between these receptor components in the tested systems.[3]

However, the exact receptor structure is still debated. Cheung Tung Shing et al. (2018) tested the purified extracellular domains of EPOR and CD131 using multiple biophysical methods—analytical size-exclusion chromatography, pull-down assays, microscale thermophoresis (MST), surface plasmon resonance (SPR), and analytical ultracentrifugation (AUC)—and did not find evidence that they directly associate with each other, either in the presence of EPO or in the presence of ARA-290.

The study also tested ARA-290 specifically in pull-down, MST, and SPR experiments; none of these methods detected EPOR–CD131 association promoted by ARA-290.[4] EPOR homodimer formation served as a positive control (Kd = 166 ± 16 nM by MST).[4]

For this reason, it is safer and more accurate to describe EPOR/CD131 as a proposed functional receptor model. Articles should not state that a stable EPOR/CD131 heterodimer has been fully proven at the structural level.

What Laboratory Studies Have Reported

Cell studies have examined ARA-290 in models exposed to heat, oxidative stress, inflammatory signals, and other controlled laboratory conditions. Bohr et al. (2015) tested ARA-290 in several mouse mesenchymal-derived cell types, including adipose fibroblasts (mAFB), bone marrow mesenchymal stem cells (mBMSC), and a macrophage cell line (mJ774), as well as human microvascular endothelial cells (hMEC).

Stress conditions included lipopolysaccharide (LPS), TNFα, tert-butyl hydroperoxide (BHP, 0.1–100 μM for 2 hours), and heat shock (65°C / 20 seconds for mAFB; 55°C / 10 seconds for hMEC). Under these conditions, ARA-290 modulated IL-6 and TNFα secretion, cell survival after heat shock and oxidative stress, and the activity of transcription factors including serum response factor (SRF), heat shock transcription factor 1 (HSF1), and activator protein 1 (AP1).[5]

Conflict-of-interest note: two authors of this study (M. Brines and A. Cerami) reported serving as officers of Araim Pharmaceuticals and holding company stock. The findings should therefore be interpreted together with independent replication and the study’s experimental limitations.[5]

These findings came from specific cell types, test conditions, concentrations, and measurement methods. They do not prove that the same result will appear in every cell line.

They also do not establish safety, effectiveness, or suitability for any human or veterinary application.

Animal-model findings must be described in the same limited way. A result seen in a laboratory animal model shows what happened in that model.

It should not be presented as a confirmed result in humans.

Planning an In-Vitro Study

An ARA-290 experiment should begin with a clear research question. Researchers should not assume that adding the peptide will automatically activate a particular receptor or pathway.

  • Record the supplier, batch number, sequence, counterion form, HPLC purity, and peptide content.
  • Confirm that the cell model expresses the receptor components being studied.
  • Use several peptide concentrations instead of relying on one concentration.
  • Include untreated, vehicle, and stress-only controls where relevant.
  • Measure cell viability so that toxicity is not mistaken for a pathway-specific effect.
  • Use more than one test when making a receptor or pathway claim.
  • Repeat the experiment independently and report the number of repeats.

A change in one downstream marker does not prove direct receptor binding. For example, a change in STAT, Akt, NF-κB, or cytokine measurements may show that a signaling response occurred, but it does not identify the exact receptor complex by itself.

Quality Control for Inflammatory and Parenteral Studies

For immune, inflammatory, or cytokine-related studies (such as those measuring TNFα, IL-6, or stress-related transcription factors), bacterial endotoxin contamination can itself induce inflammatory and cytokine responses, potentially confounding the interpretation of peptide effects. The following should be recorded:

  • Batch endotoxin result, test method (e.g., LAL or rFC), reporting unit (EU/mg or EU/vial), sample concentration tested, and method-suitability or spike-recovery result.
  • For parenteral animal studies: use an appropriately sterile formulation and document endotoxin, sterility or bioburden as applicable, pH, osmolality, particulate appearance, filtration conditions, and peptide recovery after filtration.

These are not universal release requirements for all research-use-only lyophilized peptides; they are critical quality attributes selected according to the experimental application.

Storage and Solution Preparation

The batch-specific storage instructions should always take priority. When no validated batch instruction is available, a common conservative laboratory practice is to keep unopened lyophilized peptide stored at approximately −20 °C or below in a dry, tightly closed, light-protected container, unless the batch-specific documentation specifies otherwise.

  • Allow the sealed vial to warm before opening it to reduce moisture condensation.
  • Keep the dry peptide away from humidity.
  • Record the storage temperature and any temperature changes.
  • Do not assign a shelf life without stability data.

ICH Q1A(R2) is written for regulated drug substances and products, not for research peptides. However, it explains an important general quality principle: storage periods and retest dates should be supported by stability data.[6]

ARA-290 solubility can change with the batch form, concentration, pH, salt level, and buffer. Researchers should not assume that every batch will dissolve at the same concentration in water or PBS.

  • Test solubility with a small amount before preparing the full stock.
  • Record the buffer, pH, concentration, temperature, and mixing method.
  • Check for cloudiness, particles, or precipitation.
  • Use low-binding laboratory tubes when peptide loss to the container is a concern.
  • Prepare small aliquots to reduce repeated freeze-thaw cycles.

A storage temperature such as −80 °C does not automatically prove that a prepared solution will remain stable for a particular number of days or months. Solution stability should be evaluated using a validated or appropriately qualified stability-indicating quantitative method, typically RP-HPLC or UPLC capable of separating intact peptide from degradation products.

LC-MS or other mass-spectrometric methods may be used as orthogonal tools for identity and degradation-product characterization, or as quantitative methods when specifically validated for that purpose.

Stock Concentration Calculations

The following equations are only for laboratory stock preparation. They are not human or veterinary dosing calculations.

If the COA gives a peptide-content value for the batch, the peptide-equivalent mass should be calculated first:

Peptide-equivalent mass = gross weighed material mass × peptide-content fraction

For example, a peptide-content value of 80% is entered as 0.80. HPLC area purity should not automatically be used as the peptide-content value because these two measurements describe different properties.

This calculation is valid only when peptide content is defined as the mass fraction of free-peptide equivalent.

The molar quantity and concentration are then calculated from the peptide-equivalent mass:

Moles of ARA-290 = peptide-equivalent mass / 1,257.3 g/mol

Concentration in mol/L = moles of ARA-290 / final volume in liters

Required gross material mass = target concentration in mol/L × final volume in liters × 1,257.3 g/mol / peptide-content fraction

How to Read the COA

A COA gives test results for one batch. It does not prove that every batch has the same quality, and it does not show that the material is suitable for human, veterinary, cosmetic, or diagnostic use.

COA Item What It Shows What It Does Not Show by Itself
Batch number Which production batch was tested Identity or purity
Sequence The sequence the product is meant to contain Proof that the batch matches the sequence
Mass spectrometry Whether measured ions match the expected molecular mass HPLC purity, peptide content, or solution stability
HPLC purity Relative peak area under the stated HPLC method Identity, total peptide mass, or absence of every impurity
Peptide content The amount of peptide compared with the total material weight Molecular identity
Water content How much measured moisture is present Residual solvent or counterion content
Counterion content The measured amount of acetate, trifluoroacetate, or another counterion Total organic impurity levels
Residual solvents Levels of the solvents included in the test Absence of solvents that were not tested
Endotoxin Measured bacterial endotoxin level, when tested Sterility, bioburden, or the absence of non-endotoxin pyrogens

HPLC results depend on the column, mobile phase, gradient, flow rate, detector, sample amount, and peak-integration rules. An HPLC purity number should therefore be linked to the method used.

Mass spectrometry is mainly used to support identity. The COA should make clear whether it reports a calculated mass, a measured ion, a charge state, or a reconstructed neutral mass.

ICH Q2(R2) describes general principles for checking whether an analytical method is suitable for its purpose, including specificity, accuracy, precision, and range.[7] ICH Q14 also explains that an analytical method should be developed around the purpose of the test and the quality property being measured.[8]

Residual-solvent testing should focus on solvents used or likely to remain from synthesis, purification, and drying. ICH Q3C(R9) classifies residual solvents by toxicological risk and provides permitted daily exposure (PDE) limits for pharmaceutical materials.[9]

ICH Q3C solvent classifications and toxicological principles may be used to prioritize which process solvents should be monitored. However, PDE-derived concentration limits are intended for pharmaceutical exposure assessment and should not be adopted directly as research-use-only peptide specifications without an appropriate dose or exposure context.

Limits of the Evidence

  • ARA-290 has a defined sequence, formula, average molecular weight, monoisotopic mass, and CAS number.[1]
  • It was designed from eight residues of EPO helix B (QEQLERAL) and three residues from the adjacent BC loop (NSS), with the N-terminal Gln cyclized to pyroglutamate.[2]
  • Some studies support a functional role for EPOR and CD131 in selected laboratory models; βcR knockout mice lost tissue-protective responses to EPO and CEpo.[3]
  • Direct binding between the extracellular domains of EPOR and CD131 has not been confirmed by multiple biophysical methods (SEC, pull-down, MST, SPR, AUC), either alone or with EPO or ARA-290 present, so the exact receptor structure remains uncertain.[4]
  • Cell-study results apply only to the tested cell types, concentrations, and experimental conditions.[5]
  • A COA describes laboratory test results for one batch. It does not prove human or veterinary safety.

Research References

  1. National Center for Biotechnology Information. PubChem Compound Summary for Cibinetide, CID 91810664. https://pubchem.ncbi.nlm.nih.gov/compound/91810664
  2. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences. 2008;105(31):10913–10918. PMC2504825
  3. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences. 2004;101(41):14907–14912. doi:10.1073/pnas.0406491101. PubMed 15456912
  4. Cheung Tung Shing KS, Broughton SE, Nero TL, Gillinder K, Ilsley MD, Ramshaw H, Lopez AF, Griffin MDW, Parker MW, Perkins AC, Dhagat U. EPO does not promote interaction between the erythropoietin and beta-common receptors. Scientific Reports. 2018;8:12457. doi:10.1038/s41598-018-29865-x. PubMed 30127368
  5. Bohr S, Patel SJ, Vasko R, Shen K, Iracheta-Vellve A, Lee J, Bale SS, Chakraborty N, Brines M, Cerami A, Berthiaume F, Yarmush ML. Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. Journal of Molecular Medicine. 2015;93(2):199–210. doi:10.1007/s00109-014-1218-2. PubMed 25373867
  6. U.S. Food and Drug Administration. Q1A(R2) Stability Testing of New Drug Substances and Products. FDA guidance
  7. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA guidance
  8. U.S. Food and Drug Administration. Q14 Analytical Procedure Development. FDA guidance
  9. U.S. Food and Drug Administration. Q3C(R9) Impurities: Guidance for Residual Solvents. FDA guidance

Research Use Only Disclaimer

Research Use Only: The ARA-290 material described on this page is supplied for laboratory research purposes only and not FDA-approved for human use. This article provides general scientific information regarding standard laboratory research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.